信迪利单抗联合含铂化疗治疗晚期NSCLC患者的疗效及对血清Notch1、Dickkopf-1水平的影响

doi:10.3969/j.issn.1001-8131.2026.01.006

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (611 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the efficacy of sintilimab combined with platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC)patients and its impact on serum Notch1 and Dickkopf-1 levels. Methods A total of 106 patients with advanced NSCLC admitted from selected and randomly divided into two groups using a random number table.The single group was treated with platinum-based chemotherapy,while the combination group was treated with sintilimab combined with platinum-based chemotherapy.The objective response rate,disease control rate,Notch1 mRNA,Dickkopf-1,T lymphocyte subsets,tumor markers,and adverse reaction rates were compared between the two groups. Results The disease control rate was higher in the combination therapy group than in the single-agent group(P<0.05).There was no significant difference in objective response rates between the two groups(P>0.05).Pre-treatment study-related indicators showed no significant differences between the two groups(P>0.05).After three treatment cycles,both groups showed decreased Notch1 mRNA and Dickkopf-1 levels compared to baseline.The combined therapy group exhibited lower levels than the single-agent group after three cycles(P<0.05).After three treatment cycles,the combined therapy group exhibited higher CD3⁺,CD4⁺,and CD4⁺/CD8⁺ ratios compared to pre-treatment levels and the monotherapy group after three cycles.Conversely,CD8⁺ levels were lower than pre-treatment and monotherapy group levels after three cycles(P<0.05).No significant differences were observed in T lymphocyte subsets between monotherapy groups before and after treatment(P>0.05).After three treatment cycles,both groups showed decreased levels of carbohydrate antigen 125(CA125),squamous cell carcinoma antigen(SCCA),and carcinoembryonic antigen(CEA)compared to baseline.The combined therapy group exhibited lower levels than the single-therapy group after three cycles(P<0.05).The incidence of adverse reactions was comparable between groups(3.77% in the single-agent group vs.7.55%in the combination group;P>0.05). Conclusion Sintilimab combined with platinum-based chemotherapy in the treatment of advanced NSCLC can improve immune function,inhibit the expression of Notch1,Dickkopf-1,and tumor markers,and increase the objective response rate.

Key words： Sintilimab Chemotherapy Non-small cell lung cancer T lymphocyte subsets Tumor markers

Received: 04 February 2026

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Kang Lihua
	Zhai Fengyu
	Liu Yuefen

Cite this article:

Kang Lihua,Zhai Fengyu,Liu Yuefen. The Efficacy of Sintilimab Combined with Platinum-based Chemotherapy in the Treatment of Advanced NSCLC Patients and Its Influence on Serum Notch1 and Dickkopf-1 Levels[J]. journal1, 2026, 46(1): 20-24.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2026.01.006 OR http://www.hrbyybjb.org.cn/EN/Y2026/V46/I1/20

[1] 中华医学会,中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肺癌临床诊疗指南(2021版)[J].中华肿瘤杂志,2021,101(23):1725-1757.
[2] 王正,王娟,郭春惠,等.应用RECIST1.1评价标准评估晚期非小细胞肺癌化疗疗效[J].影像研究与医学应用,2017,1(7):54-55.
[3] 皋文君,刘砚燕,袁长蓉.国际肿瘤化疗药物不良反应评价系统——通用不良反应术语标准4.0版[J].肿瘤,2012,32(2):142-144.
[4] Siegel RL,Miller KD,Fuchs HF,et al.Cancer Statistics,2021[J].CA Cancer J Clin,2021,71(1):7-33.
[5] 刘真,陈诚.紫杉醇3周给药联合顺铂化疗对非小细胞肺癌患者miR-564、miR-219表达及预后的影响[J].川北医学院学报,2023,38(1):122-125.
[6] 卯云烨,盛舒,王安,等.老年晚期NSCLC患者PD-1/PD-L1免疫检查点抑制剂治疗现状及展望[J].中国肺癌杂志,2024,27(5):367-375.
[7] 杨敏伟,曾冬香,杨全良,等.信迪利单抗在晚期非小细胞肺癌化疗患者中的应用及对其血清细胞因子、免疫功能的影响[J].中国临床药理学杂志,2022,38(24):2931-2935.
[8] Chmielewska I,Grenda A,Krawczyk P,et al.The in-fluence of plas ma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients[J].Cancer Immunol Immunother,2023,72(12):4169-4177.
[9] 桂国华,畅龙,胡炎兴,等.血清CEA、Dickkopf-1检测联合低剂量螺旋CT扫描在肺癌早期诊断中的价值分析[J].中国CT和MRI杂志,2022,20(1):67-70.
[10] 周宗正,潘刚,乙楠,等.CA125、CYFRA21-1、AFR水平与晚期非小细胞肺癌化疗预后的关系[J].分子诊断与治疗杂志,2024,16(6):1019-1023.
[11] 高翔宇,田添.血清SCCA、ProGRP、NSE与老年非小细胞肺癌患者病理特征及化疗客观疗效的相关性分析[J].中华保健医学杂志,2024,26(4):452-455.
[12] 燕磊,李洁平,赵震焱.血清NSE、CEA、CYFRA21-1水平对非小细胞肺癌的诊断价值[J].实用癌症杂志,2025,40(1):58-60.
[13] 郑传会,林莉,汪霞,等.Wnt/β-catenin信号通路在miR-21介导的非小细胞肺癌顺铂耐药性中的作用[J].西安交通大学学报(医学版),2025,46(2):238-248.
[14] 高红婷,胡梦雪,贾琳琳,等.信迪利单抗联合化疗一线治疗晚期或复发性非小细胞肺癌的成本-效用分析[J].中国药房,2022,33(15):1854-1859.
[15] 吕志芳,王明,程飞飞,等.中性粒细胞/淋巴细胞CD4+/CD8+与PD-1抑制剂免疫治疗肺癌疗效及OS的关系研究[J].河北医学,2024,30(9):1483-1488.
[16] 林恒,谢强.PD-1抑制剂一线治疗晚期非小细胞肺癌的疗效和安全性[J].中国新药与临床杂志,2021,40(6):436-440.